Free Trial
NASDAQ:BDSX

Biodesix (BDSX) Stock Price, News & Analysis

Biodesix logo
$1.30
-0.40 (-23.53%)
(As of 11/1/2024 ET)

About Biodesix Stock (NASDAQ:BDSX)

Key Stats

Today's Range
$1.28
$1.67
50-Day Range
$1.30
$1.96
52-Week Range
$1.15
$2.21
Volume
554,657 shs
Average Volume
149,748 shs
Market Capitalization
$188.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.06
Consensus Rating
Buy

Company Overview

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Biodesix Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
62nd Percentile Overall Score

BDSX MarketRank™: 

Biodesix scored higher than 62% of companies evaluated by MarketBeat, and ranked 433rd out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Biodesix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Biodesix has only been the subject of 1 research reports in the past 90 days.

  • Read more about Biodesix's stock forecast and price target.
  • Earnings Growth

    Earnings for Biodesix are expected to grow in the coming year, from ($0.36) to ($0.26) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Biodesix is -2.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Biodesix is -2.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Biodesix has a P/B Ratio of 26.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.29% of the outstanding shares of Biodesix have been sold short.
  • Short Interest Ratio / Days to Cover

    Biodesix has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Biodesix has recently decreased by 1.10%, indicating that investor sentiment is improving.
  • Dividend Yield

    Biodesix does not currently pay a dividend.

  • Dividend Growth

    Biodesix does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.29% of the outstanding shares of Biodesix have been sold short.
  • Short Interest Ratio / Days to Cover

    Biodesix has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Biodesix has recently decreased by 1.10%, indicating that investor sentiment is improving.
  • News Sentiment

    Biodesix has a news sentiment score of -0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Biodesix this week, compared to 1 article on an average week.
  • Search Interest

    3 people have searched for BDSX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Biodesix to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Biodesix insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,533.00 in company stock.

  • Percentage Held by Insiders

    69.20% of the stock of Biodesix is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 20.96% of the stock of Biodesix is held by institutions.

  • Read more about Biodesix's insider trading history.
Receive BDSX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biodesix and its competitors with MarketBeat's FREE daily newsletter.

BDSX Stock News Headlines

Biodesix files to sell 62.2M shares of common stock for holders
Biodesix: Poised for Recovery and Growth Amid Temporary Setbacks
625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
Biodesix Announces Third Quarter 2024 Results and Highlights
Craig-Hallum Sticks to Its Buy Rating for Biodesix (BDSX)
See More Headlines

BDSX Stock Analysis - Frequently Asked Questions

Biodesix's stock was trading at $1.84 at the beginning of the year. Since then, BDSX stock has decreased by 29.3% and is now trading at $1.30.
View the best growth stocks for 2024 here
.

Biodesix, Inc. (NASDAQ:BDSX) posted its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.09) by $0.01. The firm had revenue of $17.93 million for the quarter, compared to the consensus estimate of $16.05 million. Biodesix had a negative net margin of 73.08% and a negative trailing twelve-month return on equity of 505.95%.

Biodesix (BDSX) raised $76 million in an initial public offering (IPO) on Wednesday, October 28th 2020. The company issued 4,200,000 shares at $17.00-$19.00 per share. Morgan Stanley and William Blair acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

Biodesix's top institutional shareholders include Perkins Capital Management Inc. (0.50%). Insiders that own company stock include Jack W Schuler, John Patience, Scott Hutton, Robin Harper Cowie, Gary Anthony Pestano, Ryan H Siurek, Kieran O'kane, Robert William Georgantas III, Chris Vazquez and Charles M Watts.
View institutional ownership trends
.

Shares of BDSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Biodesix investors own include Broadcom (AVGO), NVIDIA (NVDA), Adobe (ADBE), Arista Networks (ANET), ServiceNow (NOW), CrowdStrike (CRWD) and Meta Platforms (META).

Company Calendar

Last Earnings
8/07/2024
Today
11/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
Healthcare
Current Symbol
NASDAQ:BDSX
Fax
N/A
Employees
220
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.06
High Stock Price Target
$3.50
Low Stock Price Target
$2.80
Potential Upside/Downside
+135.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-52,150,000.00
Pretax Margin
-73.08%

Debt

Sales & Book Value

Annual Sales
$49.09 million
Book Value
$0.05 per share

Miscellaneous

Free Float
44,715,000
Market Cap
$188.73 million
Optionable
Optionable
Beta
1.22
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

This page (NASDAQ:BDSX) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners